CA3173394A1 - Methods of making chimeric antigen receptor-expressing cells - Google Patents

Methods of making chimeric antigen receptor-expressing cells

Info

Publication number
CA3173394A1
CA3173394A1 CA3173394A CA3173394A CA3173394A1 CA 3173394 A1 CA3173394 A1 CA 3173394A1 CA 3173394 A CA3173394 A CA 3173394A CA 3173394 A CA3173394 A CA 3173394A CA 3173394 A1 CA3173394 A1 CA 3173394A1
Authority
CA
Canada
Prior art keywords
cells
population
iii
car
beginning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173394A
Other languages
English (en)
French (fr)
Inventor
Jennifer BROGDON
Glenn Dranoff
Michael R. GREENE
Anniesha HACK
Olja KODRASI
Elizabeth Dorothy PRATICO
Andrew Price
Andrew Marc Stein
Amy Rayo
Jennifer Yang
Brian Walter Granda
Attilio Bondanza
Boris ENGELS
Hyungwook Lim
Akash SOHONI
Louise TREANOR
Xu Zhu
Carla Guimaraes
Shyamali JAYASHANKAR
Sandeep Tharian Koshy
Regis Cebe
Michael Bardroff
Sandra Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3173394A1 publication Critical patent/CA3173394A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3173394A 2020-02-27 2021-02-26 Methods of making chimeric antigen receptor-expressing cells Pending CA3173394A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982665P 2020-02-27 2020-02-27
US62/982,665 2020-02-27
PCT/US2021/019889 WO2021173985A2 (en) 2020-02-27 2021-02-26 Methods of making chimeric antigen receptor-expressing cells

Publications (1)

Publication Number Publication Date
CA3173394A1 true CA3173394A1 (en) 2021-09-02

Family

ID=74885109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173394A Pending CA3173394A1 (en) 2020-02-27 2021-02-26 Methods of making chimeric antigen receptor-expressing cells

Country Status (15)

Country Link
US (1) US20230256017A1 (enExample)
EP (1) EP4110376A2 (enExample)
JP (1) JP2023516008A (enExample)
KR (1) KR20220146530A (enExample)
CN (1) CN115175695A (enExample)
AR (1) AR121461A1 (enExample)
AU (1) AU2021228708A1 (enExample)
BR (1) BR112022017148A2 (enExample)
CA (1) CA3173394A1 (enExample)
CL (2) CL2022002327A1 (enExample)
IL (1) IL295604A (enExample)
MX (1) MX2022010604A (enExample)
PH (1) PH12022552283A1 (enExample)
TW (1) TW202146441A (enExample)
WO (1) WO2021173985A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
US20240327889A1 (en) * 2021-04-05 2024-10-03 Victor TETS Regulation of cells and organisms
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
WO2023076912A2 (en) * 2021-10-26 2023-05-04 ImmPACT Bio USA Inc. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies
KR20250067174A (ko) 2022-09-15 2025-05-14 노파르티스 아게 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
KR20250018373A (ko) * 2023-07-26 2025-02-05 주식회사 굳티셀 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면 단백질 Lrig-1의 용도
GB202316184D0 (en) * 2023-10-23 2023-12-06 Autolus Ltd Method
AU2024369476A1 (en) * 2023-11-03 2026-05-21 Kyverna Therapeutics, Inc. Methods for manufacture of engineered t cells from whole blood samples
CN120041501A (zh) * 2023-11-10 2025-05-27 上海细胞治疗集团药物技术有限公司 一种表达嵌合抗原受体的细胞的制备方法
CN120210284A (zh) * 2023-12-19 2025-06-27 上海细胞治疗集团股份有限公司 一种冻存细胞制备表达嵌合抗原受体的细胞的方法
WO2025191300A1 (en) 2024-03-12 2025-09-18 Novartis Ag Rapcabtagene autoleucel for use in treating systemic lupus erythematosus
WO2026069200A1 (en) 2024-09-25 2026-04-02 Novartis Ag Treatment of neuroimmune diseases using a population of cd19 car-expressing cells
WO2026088096A1 (en) 2024-10-24 2026-04-30 Novartis Ag Treatment of systemic sclerosis using a population of cd19 car-expressing cells
WO2026093896A1 (en) 2024-10-28 2026-05-07 Novartis Ag Treatment of multiple sclerosis using a population of cd19 car-expressing cells
WO2026093895A1 (en) 2024-10-28 2026-05-07 Novartis Ag Treatment of idiopathic inflammatory myopathies using a population of cd19 car-expressing cells
WO2026110060A1 (en) 2024-11-21 2026-05-28 Novartis Ag Treatment of myasthenia gravis using a population of cd19 car-expressing cells

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997031898A1 (en) 1996-02-28 1997-09-04 Ariad Gene Therapeutics, Inc. Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20040040047A1 (en) 1998-03-30 2004-02-26 Spencer David M. Regulated apoptosis using chemically induced dimerization of apoptosis factors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HK1043608B (en) 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
IN2014MN02293A (enExample) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
CN106456670B (zh) * 2014-04-25 2020-01-07 蓝鸟生物公司 制备过继性细胞疗法的改善方法
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
US20170073415A1 (en) 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
RS61406B1 (sr) 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
EP3172231B1 (en) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
RU2751362C2 (ru) * 2014-12-29 2021-07-13 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
RU2733496C2 (ru) * 2015-03-16 2020-10-02 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
CA2999070A1 (en) 2015-09-17 2017-03-23 Novartis Ag Car t cell therapies with enhanced efficacy
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
CA3009852A1 (en) * 2015-12-28 2017-07-06 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
SI3844267T1 (sl) * 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena

Also Published As

Publication number Publication date
MX2022010604A (es) 2022-09-09
AU2021228708A1 (en) 2022-09-15
JP2023516008A (ja) 2023-04-17
CN115175695A (zh) 2022-10-11
EP4110376A2 (en) 2023-01-04
KR20220146530A (ko) 2022-11-01
US20230256017A1 (en) 2023-08-17
WO2021173985A3 (en) 2021-10-21
PH12022552283A1 (en) 2024-01-22
IL295604A (en) 2022-10-01
CL2022002327A1 (es) 2023-04-10
AR121461A1 (es) 2022-06-08
WO2021173985A2 (en) 2021-09-02
CL2023002745A1 (es) 2024-04-01
TW202146441A (zh) 2021-12-16
BR112022017148A2 (pt) 2022-11-08

Similar Documents

Publication Publication Date Title
US20260034195A1 (en) Chimeric antigen receptors and uses thereof
AU2019331496B2 (en) Methods of making chimeric antigen receptor-expressing cells
US20230256017A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2026048701A (ja) キメラ抗原受容体発現細胞を作製する方法
US20250000973A1 (en) Methods of making chimeric antigen receptor-expressing cells
RU2822196C2 (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор
HK40048881B (en) Methods of making chimeric antigen receptor-expressing cells
HK40048881A (en) Methods of making chimeric antigen receptor-expressing cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250125

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250826

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260409